Susan O'Brien

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)
    Aref Al-Kali
    Leukemia Department, UT MD Anderson Cancer Center, Houston, Texas, USA
    J Blood Med 1:115-22. 2010
  2. ncbi Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
    Susan O'Brien
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Lancet Oncol 15:48-58. 2014
  3. pmc Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells
    Uri Rozovski
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer 12:50. 2013
  4. doi Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia
    Preetesh Jain
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Expert Opin Biol Ther 13:169-82. 2013
  5. ncbi Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia
    Susan O'Brien
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX 77230, USA
    Br J Haematol 158:581-8. 2012
  6. pmc Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome
    Wanlong Ma
    Department of Hematology Oncology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    BMC Med Genet 11:163. 2010
  7. doi Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia
    Susan O'Brien
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 10:361-8. 2010
  8. ncbi Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab
    Susan M O'Brien
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 7:125-30. 2006
  9. doi Ocular adnexal lymphoma and Helicobacter pylori gastric infection
    Didier Decaudin
    Department of Clinical Hematology, Institut Curie, 26 Rue d Ulm, Paris Cedex 05, France
    Am J Hematol 85:645-9. 2010
  10. ncbi Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia
    Susan O'Brien
    Division of Cancer Medicine, Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:2097-101. 2008

Collaborators

Detail Information

Publications195 found, 100 shown here

  1. pmc Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)
    Aref Al-Kali
    Leukemia Department, UT MD Anderson Cancer Center, Houston, Texas, USA
    J Blood Med 1:115-22. 2010
    ..This type of relatively nontoxic regimen is being investigated in elderly patients who may not tolerate standard combination chemoimmunotherapies...
  2. ncbi Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
    Susan O'Brien
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Lancet Oncol 15:48-58. 2014
    ..We aimed to assess safety and activity of ibrutinib, an orally administered covalent inhibitor of Bruton tyrosine kinase (BTK), in treatment-naive patients aged 65 years and older with chronic lymphocytic leukaemia...
  3. pmc Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells
    Uri Rozovski
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer 12:50. 2013
    ....
  4. doi Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia
    Preetesh Jain
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Expert Opin Biol Ther 13:169-82. 2013
    ..A type II anti-CD20 mAb, GA-101 (obinutuzumab), is currently in clinical trials. This short review focuses on ongoing clinical trials of anti-CD20 mAbs in CLL...
  5. ncbi Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia
    Susan O'Brien
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX 77230, USA
    Br J Haematol 158:581-8. 2012
    ..25% in controls. Elacytarabine has monotherapy activity in patients with advanced AML. This study provides proof-of-concept that lipid esterification of nucleoside analogues is clinically relevant...
  6. pmc Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome
    Wanlong Ma
    Department of Hematology Oncology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    BMC Med Genet 11:163. 2010
    ..The G/G genotype of the single-nucleotide polymorphism (SNP) rs1617640 in the erythropoietin (EPO) promoter has been shown to be associated with decreased EPO expression. We examined the association of rs1617640 genotype with MDS...
  7. doi Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia
    Susan O'Brien
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 10:361-8. 2010
    ..Ongoing trials will help confirm the role of ofatumumab in CLL, in addition to the effect of this agent in combination with chemotherapies and other MoAbs...
  8. ncbi Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab
    Susan M O'Brien
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 7:125-30. 2006
    ....
  9. doi Ocular adnexal lymphoma and Helicobacter pylori gastric infection
    Didier Decaudin
    Department of Clinical Hematology, Institut Curie, 26 Rue d Ulm, Paris Cedex 05, France
    Am J Hematol 85:645-9. 2010
    ..This suggests a novel mechanism of indirect infection-associated lymphomagenesis whereby chronic local antigen stimulation would lead to the emergence of ectopic B-cell lymphoma...
  10. ncbi Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia
    Susan O'Brien
    Division of Cancer Medicine, Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:2097-101. 2008
    ..Understanding the causes of failure in older patients with acute lymphocytic leukemia (ALL) may help improve treatment strategies for patients in this particular age group...
  11. ncbi Maintenance therapy for B-chronic lymphocytic leukemia
    Susan O'Brien
    Division of Hematology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 9:22-31. 2011
    ..These naturally occurring compounds are well tolerated, and they inhibit survival signals in the microenvironment necessary for tumor development, making them well suited for evaluation as maintenance therapy for CLL...
  12. ncbi Monoclonal antibodies in the treatment of lymphoid leukemia
    Susan O'Brien
    Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Drugs Today (Barc) 39:541-50. 2003
    ..Further understanding of the in-vitro mechanisms involved in tumor cell killing by MoAb will be important in maximizing the efficacy of this approach...
  13. ncbi Update: chronic myelogenous leukemia clinical practice guidelines
    Susan M O'Brien
    Leukemia Department, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Compr Canc Netw 1:S29-40. 2003
    ..However, important questions still have not been answered. For example, which patients may be cured with imatinib and which patients should still be offered transplant early in the course of their disease?..
  14. doi Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia
    Susan M O'Brien
    M D Anderson Cancer Center, Houston, TX 77030 7305 USA
    Blood 113:299-305. 2009
    ..Further evaluation in less heavily pretreated patients and in combination with other therapeutic agents is warranted. This trial has been registered with http://clinicaltrials.gov under identifier NCT00600964...
  15. ncbi Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia
    Susan M O'Brien
    M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030 7305, USA
    J Clin Oncol 23:7697-702. 2005
    ..To determine the maximum-tolerated dose (MTD), efficacy, safety, and pharmacokinetics of oblimersen sodium in patients with advanced chronic lymphocytic leukemia (CLL)...
  16. ncbi Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
    Susan M O'Brien
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2657-63. 2003
    ..The objective of this study was to investigate the efficacy and safety of alemtuzumab, the humanized anti-CD52 monoclonal antibody, in patients with B-cell chronic lymphocytic leukemia and residual disease after chemotherapy...
  17. ncbi Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy
    Susan O'Brien
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:1816-9. 2008
    ..004). In conclusion, this agent was highly effective for prophylaxis of CMV reactivation in patients receiving alemtuzumab. This trial was registered at www.ClinicalTrials.gov as #NCT00562770...
  18. ncbi Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia
    Susan O'Brien
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:1114-20. 2007
    ..We evaluated whether oblimersen would improve response to chemotherapy in patients with relapsed or refractory CLL...
  19. doi 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen
    Susan O'Brien
    Division of Hematology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:5208-12. 2009
    ..53; P = .05), was observed in patients with fludarabine-sensitive disease. We evaluated long-term survival and poststudy CLL therapy among all randomly assigned patients...
  20. ncbi Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
    Farhad Ravandi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 122:1214-21. 2013
    ..2). At 3 and 12 months, negative MRD by MFC was associated with improved survival (P = .04 and .001). MRD monitoring by PCR and MFC identifies patients who benefit from treatment intensification in first CR...
  21. ncbi Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
    Jorge Cortes
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 101:1692-7. 2003
    ..R115777 showed clinical activity in patients with CML and MF. The effect on VEGF needs to be further investigated to determine whether this might be a possible mechanism of action of R115777...
  22. ncbi Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
    Stefan Faderl
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Blood 101:3413-5. 2003
    ..The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses...
  23. ncbi Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
    Alfonso Quintas-Cardama
    Departments of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Blood 113:6315-21. 2009
    ..This risk is discernible as early as 3 months into imatinib therapy by molecular analysis and may provide the rationale to institute therapies that render higher rates of early response...
  24. ncbi Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer 106:1569-80. 2006
    ..Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens...
  25. ncbi Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:2099-108. 2005
    ..The objectives of this study were to update the long-term experience with imatinib in patients who had accelerated-phase CML and to compare outcomes with historic experience...
  26. ncbi Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 103:4396-407. 2004
    ..Molecular CRs were achieved in both groups (SCT or no SCT). Outcome with hyper-CVAD and imatinib mesylate appears better than with prior regimens; continued accrual and longer follow-up of the current cohort is needed...
  27. ncbi The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia
    Alessandra Ferrajoli
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 100:1215-9. 2002
    ..005). We conclude that the TNF-alpha level serves as a prognostic factor in patients with CLL and that inhibition of TNF-alpha in these patients could have therapeutic importance...
  28. doi HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia
    Paolo Strati
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 120:373-80. 2014
    ..Chronic myeloid leukemia (CML) may progress to blast phase (BP) at the rate of 1% to 1.5% per year. With the use of single-agent tyrosine kinase inhibitors, median overall survival ranges between 7 and 11 months...
  29. pmc Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 27:3659-63. 2009
    ..The clinical significance of increasing levels of QPCR in patients in CGCR is uncertain...
  30. pmc Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Blood 113:6330-7. 2009
    ..Incorporation of monoclonal antibodies directed against CD20 into frontline chemotherapy regimens warrants investigation...
  31. ncbi Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 104:1979-88. 2004
    ..0001); the survival advantage was confirmed by multivariate analysis (hazard ratio, 0.19; P <.0001)...
  32. ncbi Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
    Stefan Faderl
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX 77230 1402, USA
    J Clin Oncol 28:2755-60. 2010
    ..Efficacy and toxicity profile of orally administered clofarabine were evaluated in patients with higher-risk myelodysplastic syndrome (MDS)...
  33. doi Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 114:2037-43. 2009
    ..Mutation scoring can predict outcome in CML-chronic phase with imatinib failure treated with second-generation TKIs and can help in therapy selection. More complex prognostic models will be required for advanced stages of disease...
  34. ncbi Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:480-2. 2006
    ..SBT is still a rare event, probably less common than that observed with IFN-alpha therapy. Continuous monitoring of patients treated with imatinib is mandatory...
  35. ncbi Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate
    Arturo Vega-Ruiz
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Res 32:1468-71. 2008
    ..The patient then developed myelodysplastic syndrome and solitary central nervous system relapse of ALL...
  36. pmc Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy
    Naveen Pemmaraju
    Department of Leukemia, University of Texas, Anderson Cancer Center, Houston, TX 77230, USA
    Haematologica 97:1029-35. 2012
    ..Outcomes in chronic myeloid leukemia have improved with tyrosine kinase inhibitor treatment. However, little is known about outcomes of chronic myeloid leukemia in adolescent and young adult patients...
  37. ncbi Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase
    Susan O'Brien
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 98:888-93. 2003
    ....
  38. doi Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
    Apostolia M Tsimberidou
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA
    J Clin Oncol 26:196-203. 2008
    ..We conducted a phase I-II trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) in these diseases...
  39. doi Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)
    Gheath Alatrash
    Department of Stem Cell Transplantation and Cellular Therapy, U T MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 148:386-93. 2010
    ..These data further indicate that plasma may be a good target to evaluate for minimal residual disease using cCD52/cCD20 levels...
  40. ncbi Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2636-42. 2003
    ..This was most likely because approximately 90% of patients receiving IFN-alpha plus ara-C changed to imatinib therapy after a median of 8 months into therapy...
  41. ncbi Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha
    Jorge Cortes
    Department of Leukemia and Bioimmunotherapy, M D Anderson Cancer Center, University of Texas Houston, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:83-6. 2003
    ..In conclusion, high-dose imatinib induces complete cytogenetic responses in most patients with chronic-phase CML after interferon failure. This is accompanied by a high rate of molecular remission...
  42. ncbi Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience
    Bryan Hennessy
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Hematol 77:209-14. 2004
    ..SM is rare and has no effective standard of care. Collaboration among academic centers to accrue enough patients to evaluate novel therapeutic strategies is needed...
  43. ncbi Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
    Hagop Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA
    Cancer 112:837-45. 2008
    ..Response rates in chronic myeloid leukemia (CML) are now reported based on the cumulative incidence of a single-time best response. The study aim was to examine the significance of different response criteria for CML on imatinib therapy...
  44. ncbi Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes
    Alvaro Aguayo
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 95:1923-30. 2002
    ..Increased levels in urine, serum, plasma, or malignant tissue have been associated with an adverse prognosis in patients with solid tumors...
  45. ncbi Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 10:68-75. 2004
    ..Multivariate analyses were conducted to assess the independent prognostic effect of therapy (imatinib versus other) on survival...
  46. ncbi Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
    Alfonso Quintas-Cardama
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:248-55. 2007
    ..Homoharringtonine (HHT) is a cephalotaxus alkaloid that inhibits the synthesis of proteins leading to apoptosis. Intravenous HHT has demonstrated activity in patients with chronic myeloid leukemia (CML) after failure with interferon...
  47. ncbi Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
    Carmen Fava
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:5058-63. 2009
    ..These results suggest that achievement of a MCyR without concomitant CHR is associated with poor outcome...
  48. ncbi Activity of alemtuzumab in patients with CD52-positive acute leukemia
    Raoul Tibes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:2645-51. 2006
    ..Because CD52 also is expressed on acute leukemic blasts, the authors investigated the safety and efficacy of alemtuzumab in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)...
  49. ncbi Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
    Apostolia M Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 52:449-52. 2003
    ..The Mylotarg, fludarabine, cytarabine, and cyclosporine (MFAC) regimen was evaluated in patients in complete remission following Mylotarg-containing regimens...
  50. ncbi Biphenotypic acute leukaemia: a case series
    Ahmed Aribi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston TX 77030, USA
    Br J Haematol 138:213-6. 2007
    ..Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%...
  51. pmc Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia
    Elias Jabbour
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 12:244-51. 2012
    ..The overall 4-week mortality rate was 9%. In conclusion, BIDFA is active and safe in heavily pretreated patients with myeloid malignancies...
  52. ncbi Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
    Stefan Faderl
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 108:45-51. 2006
    ..However, survival does not appear to be improved compared with other regimens. Modifications of this combination in AML therapy of older patients warrant further evaluation...
  53. ncbi Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 106:1099-109. 2006
    ..Topotecan-cytarabine regimens have shown encouraging results in higher-risk MDS. The aim of this study was to analyze the long-term results with topotecan-cytarabine versus other intensive chemotherapy regimens in higher-risk MDS...
  54. ncbi Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen
    Deborah Thomas
    Department of Leukemia, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4580-9. 2010
    ..5 g/m2 IV on Days 1 and 2) to the standard hyper-CVAD regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high dose methotrexate and cytarabine) would improve outcome...
  55. pmc Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia
    Deborah A Thomas
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:3880-9. 2010
    ....
  56. ncbi A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome
    Elias Jabbour
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1236-44. 2011
    ..The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome...
  57. ncbi The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy
    Yue Wei
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 16:3923-32. 2010
    ..We hypothesized, therefore, that combination of an HDACi with a proapoptotic agent, such as the Bcl-2 homology domain-3 mimetic GX15-070, could result in enhanced antileukemia activity...
  58. ncbi Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
    Jorge E Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 101:3794-800. 2003
    ..The 3-month cytogenetic response to imatinib mesylate refined the prognostic relevance of such studies in patients on imatinib mesylate therapy...
  59. ncbi Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2225-8. 2003
    ..Because early allogeneic stem cell transplantation (SCT) may be associated with a better outcome, early parameters predicting for subsequent cytogenetic responses would optimize the treatment decision-making...
  60. ncbi Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:2154-60. 2009
    ..In conclusion, imatinib dose escalation can induce sustained responses in a subset of patients with cytogenetic failure and a previous cytogenetic response to standard-dose imatinib...
  61. pmc Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
    Hagop Kantarjian
    Department of Leukemia, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:1981-7. 2012
    ..Imatinib therapy minimized the impact of known prognostic factors and Sokal risk in CP-CML and accentuated the impact of age in AP- and BP-CML...
  62. ncbi Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 117:1822-7. 2011
    ..This scoring system could serve to advise patients of their prognosis and treatment options, as well as to evaluate the benefit of newer alternate options...
  63. ncbi A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase
    Alfonso Quintas-Cardama
    Department of Leukemia, The University of Texas M D Anderson Cancer Center Houston, TX 77030, USA
    Leuk Lymphoma 48:283-9. 2007
    ..Median survival was 5 months (range, 2 - 20 months). This outpatient regimen is effective and well tolerated and perhaps superior to single-agent imatinib for patients in myeloid BP...
  64. ncbi Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors
    Dan Jones
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:985-94. 2008
    ..Patterns of KD mutations in Philadelphia chromosome (Ph)-positive acute lympho- blastic leukemia (ALL) are less well studied...
  65. ncbi Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:265-73. 2007
    ..In this study, the authors update their experience with decitabine in patients with MDS and analyze the cytogenetic response patterns and prognostic factors associated with decitabine therapy...
  66. ncbi Outcome of patients with acute myelogenous leukemia after second salvage therapy
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Cancer 104:547-54. 2005
    ..The authors analyzed the outcome of patients with AML undergoing second salvage therapy, and identified prognostic factors associated with response and survival...
  67. ncbi Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
    Constantine S Tam
    Departments ofLeukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:975-80. 2008
    ..5% per year for the third year onward. In a multivariate analysis of patients receiving fludarabine-based therapy at our center, FCR therapy emerged as the strongest independent determinant of survival...
  68. ncbi Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
    Hagop Kantarjian
    Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 109:52-7. 2007
    ..We conclude that a low-dose, dose-intensity schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS...
  69. ncbi Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
    Stefan Faderl
    Department of Leukemia, Box 428, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 105:940-7. 2005
    ..The combination of clofarabine with ara-C is safe and active. Cellular pharmacology data support the biochemical modulation strategy...
  70. ncbi Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation
    Apostolia Maria Tsimberidou
    Department of Leukemia, Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:2343-51. 2006
    ..The purpose of this study was to assess the incidence, presenting characteristics, and treatment outcomes of Richter's syndrome (RS) and factors predicting response and survival...
  71. ncbi Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:2788-801. 2004
    ..The current analysis updated the long-term results with the original hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) program, with a median follow-up time of 63 months...
  72. ncbi Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy
    Gloria N Mattiuzzi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 100:568-73. 2004
    ..v. ITRA) reduced the incidence of probable/proven fungal infections in this group of patients, and compare the results with those of a historic control group treated with fluconazole plus itraconazole capsules (F+I)...
  73. doi Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:5490-8. 2009
    ..Vincristine (VCR) sulfate liposomes injection (VSLI) is a sphingomyelin/cholesterol nanoparticle encapsulated VCR formulation that improves the pharmacokinetic profile of VCR without augmenting neurotoxicity...
  74. ncbi Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms
    Farhad Ravandi
    Departments of Leukemia, Hematopathology, Biostatistics, Infectious Diseases, and Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:5425-30. 2009
    ..To examine the efficacy and safety of the combination of alemtuzumab and pentostatin in patients with T-cell neoplasms...
  75. ncbi Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 104:1624-30. 2004
    ..Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease...
  76. ncbi Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia
    William G Wierda
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 29:4088-95. 2011
    ..We continue to use criteria for active disease to initiate therapy. Multivariable analysis was performed to identify prognostic factors independently associated with time to first treatment for patients with CLL...
  77. pmc Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1133-7. 2007
    ..The comparative efficacy of these 2 forms of treatment in MDS is unknown. The objective of the current study was to compare the efficacy and toxicity profiles of decitabine and intensive chemotherapy in MDS...
  78. pmc Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 28:1856-62. 2010
    ..Plasma inhibitory assay demonstrated an on-target effect on FLT3 kinase activity. CONCLUSION Sorafenib can be safely combined with chemotherapy, produces a high CR rate in FLT3-mutated patients, and inhibits FLT3 signaling...
  79. ncbi Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:1105-13. 2003
    ....
  80. ncbi Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    William Wierda
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 23:4070-8. 2005
    ..The purpose of this study was to improve the complete remission (CR) rate for previously treated patients and evaluate the quality of bone marrow response...
  81. ncbi Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, 77230 1402, USA
    Br J Haematol 134:58-60. 2006
    ..The EPI is reproducible and useful...
  82. ncbi Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
    Constantine S Tam
    Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:516-8. 2008
    ..These results suggest that patients receiving 2TKI with no cytogenetic response at 3 to 6 months should be considered for alternative therapies...
  83. pmc Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:1370-8. 2008
    ..In the current study, the authors addressed this question by matching MS patients with analogous AML patients and comparing their clinical outcomes...
  84. ncbi A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens
    William Wierda
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:337-45. 2006
    ..The objective of the current analysis was to determine whether improvements in treatment have had an impact on survival for patients with CLL...
  85. ncbi p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy
    Ellen J Schlette
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 50:1597-605. 2009
    ..In this patient cohort, p53-IHC is an important determinant of complete remission and overall survival, but not remission duration, in patients with CLL receiving FCR...
  86. ncbi Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia
    Sameer A Parikh
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 118:2062-8. 2011
    ..Response rates and survival are comparable with historic high-risk FCR-treated patients. CFAR may be a useful frontline regimen to achieve CR in patients with 17p deletion before allogeneic stem cell transplantation...
  87. ncbi Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
    Hagop Kantarjian
    Department of Leukemia, Anderson Cancer Center, Houston, TX, USA
    Blood 102:2379-86. 2003
    ..03). This increased only in responders (median, 1.8-fold; P =.008) after the second clofarabine infusion. In summary, clofarabine is active in acute leukemias and MDS; cellular pharmacokinetics may have prognostic significance...
  88. ncbi Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
    Fabio P S Santos
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 150:303-12. 2010
    ..Further studies are required to determine whether there might be a minimum adequate dose of these agents...
  89. ncbi Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
    Apostolia Tsimberidou
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Leuk Res 27:893-7. 2003
    ..CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML...
  90. ncbi Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 50:497-500. 2002
    ..Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML...
  91. ncbi Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
    Karen W L Yee
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 11:6615-24. 2005
    ..A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of ABT-751 in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias...
  92. ncbi New drugs in acute myeloid leukemia
    Francis J Giles
    Section of Developmental Therapeutics, Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Curr Oncol Rep 4:369-74. 2002
    ..Those agents targeting vascular endothelial growth factor are also briefly reviewed...
  93. ncbi Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment
    Apostolia Maria Tsimberidou
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Leuk Res 27:375-80. 2003
    ..No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study...
  94. ncbi Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
    Francis J Giles
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 21:1722-7. 2003
    ..A prospective, randomized study was conducted in patients aged 50 years or older with untreated, adverse karyotype, acute myeloid leukemia (AML) to assess troxacitabine-based regimes as induction therapy...
  95. ncbi Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome
    Srdan Verstovsek
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 118:151-6. 2002
    ..These data suggest that VEGF expression, rather than the expression of its receptors, is the determining factor in the biological behaviour of AML and MDS, and that VEGFRs are differentially expressed in AML and MDS...
  96. ncbi Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia
    Francis J Giles
    Department of Leukemia, Box 428, University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 2:630-40. 2002
    ..Gemtuzumab ozogamicin-based combinations should not be prescribed outside the research setting until further data is available...
  97. ncbi New agents in myelodysplastic syndromes
    Elias J Jabbour
    Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77063, USA
    Curr Hematol Rep 4:191-9. 2005
    ..Further development of rational therapies and improvements in the outcome of patients with MDS are likely to emerge from an increased understanding of the pathophysiology of these diseases...
  98. ncbi EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation
    Jingxuan Pan
    The University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 109:315-22. 2007
    ..We conclude that EXEL-0862 is active against KIT activation loop mutants and is a promising candidate for the treatment of patients with SM and other KIT-driven malignancies harboring active site mutations...
  99. ncbi Troxacitabine activity in extramedullary myeloid leukemia
    Yesid Alvarado
    Department of Leukemia, M D Anderson Cancer Center, The University of Texas, Houston 77030, USA
    Hematology 7:179-85. 2002
    ..Troxacitabine-based therapy had significant antileukemic activity in extramedullary myeloid leukemias and warrants further investigation in this clinical situation...
  100. ncbi The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 30:801-11. 2006
    ..AG-01736 had minimal biologic or clinical activity in this elderly patient population...
  101. ncbi Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 21:1050-6. 2003
    ..Troxacitabine has significant single-agent activity. This study was conducted to define the dose-limiting toxicities (DLTs) of its combination with cytarabine (ara-C), idarubicin, or topotecan...